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Abstract 
Background: Tanzania abandoned sulfadoxine‑pyrimethamine (SP) as the first‑line treatment for uncomplicated 
malaria in 2006 due to high levels Plasmodium falciparum resistance. However, SP is still being used for intermittent 
preventive treatment during pregnancy (IPTp‑SP). This study aimed to assess the pattern of P. falciparum dihydrofolate 
reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations and associated haplotypes in areas with different 
malaria transmission intensities in mainland Tanzania, 6 years after withdrawal of SP as a first‑line treatment regimen 
for uncomplicated malaria.
Methods: A total of 264 samples were collected during cross‑sectional surveys in three districts of Muheza, Muleba 
and Nachingwea in Tanga, Kagera and Lindi regions, respectively. Parasite genomic DNA was extracted from P. 
falciparum positive samples. The Pfdhfr, Pfdhps single nucleotide polymorphisms (SNPs) were amplified using nested 
polymerase chain reaction and detected by sequence specific oligonucleotide probe‑enzyme linked immunosorbent 
assay (SSOP‑ELISA).
Results: The prevalence of the mutant Pfdhfr‑Pfdhps haplotypes was heterogenous and transmission dependent. The 
triple Pfdhfr mutant haplotypes (CIRNI) were predominant in all sites with significantly higher frequencies at Muheza 
(93.3 %) compared to Muleba (75.0 %) and Nachingwea districts (70.6 %), (p < 0.001). Overall, the prevalence of the 
wild‑type Pfdhps (SAKAA) haplotype was lowest at Muheza (1.3 %), (p = 0.002). Double Pfdhps haplotype SGEAA was 
significantly high at Muheza (27.2 %) and Muleba (20.8 %) while none (0 %) was detected at Nachingwea (p < 0.001). 
The prevalence of triple Pfdhps SGEGA haplotype was significantly higher at Muheza compared to Muleba and 
Nachingwea (p < 0.001). In contrast, Nachingwea and Muleba had significantly higher prevalence of another triple 
Pfdhps AGEAA haplotype (χ2 = 39.9, p < 0.001). Conversely, Pfdhfr‑Pfdhps as quintuple and sextuple haplotypes were 
predominant including the emergence of a septuple mutant haplotype CIRNI‑AGEGA (n = 11) observed at Muheza 
and Muleba.
Conclusion: These results ascertain the high prevalence and saturation of Pfdhfr and Pfdhps haplotypes conferring 
SP resistance in areas with changing malaria epidemiology; and this could undermine the use of IPTp‑SP in improving 
pregnancy outcomes. In these settings where high level SP resistance is documented, additional control efforts are 
needed and evaluation of an alternative drug for IPTp is an urgent priority.
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dihydropteroate synthetase (DHPS) enzymes [13, 14]. 
Notably, several single nucleotide polymorphisms (SNPs) 
in the Pfdhps gene at codons Serine 436 to Alanine 
(S436A), Alanine 437 to Glycine (A437G), Lysine 540 
Glutamic acid (K540E), Alanine 581 to Glycine (A581G) 
and Alanine 613 to Serine (A613S) are associated with 
sulfadoxine resistance. Pyrimethamine resistance is con-
ferred by mutations in the Pfdhfr gene resulting from 
amino acid substitution at codons Cysteine 50 to Argi-
nine (C50R), Asparagine 51 to Isoleucine (N51I), Cysteine 
59 to Arginine (C59R), Serine 108 to Asparagine/Threo-
nine (S108 N/T), and Isoleucine 164 to Leucine (I164L) 
[15, 16]. Emergence and subsequent accumulation of the 
mutations in both the Pfdhfr/Pfdhps genes is associated 
with SP clinical TF in several epidemiological settings [11, 
17–19]. The major Pfdhfr haplotypes emerge as a result of 
combination of mutations of the wildtype cysteine-aspar-
agine-cysteine-asparagine-isoleucine (CNCNI) followed 





leucine (CIRNL) as a single, double, triple and quadru-
ple mutants, respectively (at amino acid positions C50R, 
N51I, C59R, S108N, and L164I) [20, 21]. For Pfdhps, the 
wild type genotype serine-alanine-lysine-alanine-alanine 
(SAKAA) can change to a single alanine–alanine-lysine-
alanine-alanine or serine-glycine-lysine- alanine–ala-
nine (AAKAA or SGKAA), double (AGKAA, SGKGA 
or SGEAA) or triple mutants (AGEAA or SGEGA, at 
amino acid positions S436A, A437G, K540E, A581G and 
A613S/T) [14, 22, 23]. Quintuple mutations as a result of 
the combination of Pfdhfr triple (CIRNI) and the Pfdhps 
double (A437G, K540E) mutations were reported in East 
Africa [24, 25] and have been shown to confer high level 
SP resistance rendering SP ineffective for treatment of P. 
falciparum infections. In northeastern Tanzania, the rise 
in Pfdhps mutations at codons A581G has led to higher 
proportions of SGEGA haplotypes [26]. Combined Pfd-
hfr-Pfdhps SGEGA-CIRNI forming the sextuple haplo-
type has been associated with sub-optimal prophylactic 
effect and thus poor pregnancy outcomes particularly in 
areas where SP resistance is widespread in sub-Saharan 
Africa [17, 18, 27].
In fact, WHO recommends stopping IPTp-SP in areas 
where the Pfdhfr K540E prevalence is >95 % and Pfdhps 
A581G is >10 % as SP is likely to be ineffective [28]. The 
Background
Plasmodium falciparum malaria remains a major pub-
lic health problem in the sub-Saharan Africa (SSA). 
Increased global efforts in malaria control and elimina-
tion have resulted into significant reduction in the dis-
ease burden through scaling up of control interventions 
such as use of insecticide-treated nets (ITNs), indoor 
residual spraying (IRS) and early case diagnosis and 
prompt treatment using effective anti-malarial drugs [1]. 
However, malaria control programmes are repeatedly 
challenged by rapid and widespread anti-malarial drug 
resistance [2–4]. Following the widespread drug resist-
ance to sulfadoxine-pyrimethamine (SP) and chloroquine 
(CQ) [5, 6], the World Health Organization (WHO) rec-
ommended a policy change from monotherapy to arte-
misinin-based combination therapy (ACT) [7]. Despite 
policy changes as a result of widespread drug resistance 
against SP, the drug is still being recommended for inter-
mittent preventive treatment during pregnancy (IPTp-
SP) whereby in areas of moderate to high transmission SP 
dose is given at each scheduled antenatal care (ANC) visit 
at least monthly to prevent pregnancy associated malaria 
(PAM) and improve pregnancy outcomes [8]. In addi-
tion, SP is still being used in the IPT in infants (IPTi-SP) 
to reduce malaria and anaemia among infants as well as 
seasonal malaria chemoprevention (SMC) programmes 
in some malaria endemic settings [9]. Nonetheless, the 
chemoprophylactic effectiveness of IPTp-SP, IPTi-SP and 
SMC-SP strategies against malaria control amongst the 
most vulnerable is increasingly being compromised due 
to the rapid and widespread SP-resistance.
In Tanzania, SP was introduced as the first-line anti-
malarial drug for treatment of uncomplicated falciparum 
malaria in 2001 as a result of high level chloroquine (CQ) 
resistance (CQR) and clinical treatment failures (TFs) 
[10]. However, 5  years after its introduction, the policy 
was again revised in November 2006 due to widespread 
resistance against SP and remarkable TFs [4, 11]. Thus, 
artemether-lumefantrine (AL), an ACT, was introduced 
as the first-line treatment for uncomplicated falciparum 
malaria in the mainland Tanzania [12]. The changes in 
malaria treatment policies were supported by data from 
molecular epidemiological resistance surveillance against 
CQ and SP. The in  vivo molecular surveillance ascer-
tained the treatment failures (TFs) [4, 11] with P. falcipa-
rum resistance against CQ and SP in clinical settings.
Sulfadoxine–pyrimethamine acts by inhibiting the 
P. falciparum dihydrofolate reductase (DHFR) and 
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widely spread highly resistant haplotypes including quin-
tuple (CIRNI-SGEAA) and sextuple (CIRNI-SGEGA) are 
likely to compromise effectiveness of IPTp-SP strategy. 
Continuous surveillance of SP effectiveness using molec-
ular markers is therefore, critical and should be routinely 
implemented as recommended by WHO [29].
Determination of molecular markers in the Pfdhfr and 
Pfdhps genes offers an invaluable tool for epidemiological 
surveillance of SP resistance in malaria endemic settings 
and will generate important data to assist and inform 
malaria control programmes on the status of resistance 
particularly due to emergence and rapid spread of highly 
resistant mutations and haplotypes that may highly 
compromise the usefulness of IPT strategies. This study 
aimed to assess the status of Pfdhfr-Pfdhps mutations and 
haplotypes in areas with different malaria transmission 
intensities in mainland Tanzania, 6 years after withdrawal 




The samples were collected from cross-sectional surveys 
at three sites with heterogeneous malaria transmission 
intensities in Tanzania from May to August 2013. The 
sites included Mkuzi health Centre in Muheza District 
in Tanga Region, Rubya Designated District Hospital 
(DDH), Muleba District in Kagera Region and Naching-
wea District hospital in Lindi Region. The Regions are 
located in north-eastern, north-western and southern 
zones of mainland Tanzania, respectively (Fig.  1). The 
study districts were selected based on evidence from 
the Tanzania HIV and Malaria Indicator Survey of 2012 
and represent areas with low, moderate and high malaria 
transmission intensities [30].
Study design and sampling methods
Cross-sectional studies were carried out in the period 
May–August 2013. Briefly, patients aged ≥6 months who 
Fig. 1 The map of Tanzania showing the study site and neighbouring countries
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presented at the health facilities with uncomplicated or 
complicated malaria were enrolled. Patients with history 
of fever in the past 24  h or fever at presentation (tem-
perature ≥37.5  °C) were screened for malaria and their 
demographic, clinical and parasitological information 
were collected. Laboratory screening for malaria was 
done using rapid diagnostic tests (RDT) and confirmed 
using microscopic examination of blood smears. Venous 
blood samples (3–5 ml) were collected into EDTA tubes 
for genomic analysis of malaria parasites. Thick and thin 
blood smears were prepared for detection and quantifica-
tion of malaria parasites. The smears were air-dried and 
the thin films were fixed with methanol prior to staining 
using 3  % Giemsa stain for 45  min. Slides were exam-
ined microscopically to count asexual or sexual parasites 
per 200 white blood cells (WBCs) or 500WBCs, respec-
tively. A slide was considered negative if no parasite was 
detected after examining 200 fields. Parasite density was 
calculated by multiplying the number of asexual para-
sites by 40 and sexual parasites by 16 assuming that one 
microliter of blood contained 8000 WBCs. Haemoglo-
bin measurement was done using a Hemocue® machine 
(HemoCue, Ångelholm, Sweden). All patients who tested 
microscopically positive for malaria were treated as per 
national guidelines for treatment of malaria [31]. Global 
positioning system (GPS) coordinates were recorded 
using a handheld GPS device. In Muheza District, Tanga 
Region, samples were also collected from a clinical trial 
evaluating the efficacy of AL as per study protocol [32].
DNA extraction
Blood smear microscopically positive P. falciparum 
infected blood samples were used for DNA extrac-
tion. The samples were depleted of the white blood cells 
(WBCs) using a CF11 cellulose columns as previously 
described [33]. Genomic DNA was extracted using the 
QIAamp DNA Blood Midi (Qiagen GmbH, Hilden, Ger-
many) as per manufacturer’s instructions.
Genotyping for Pfdhps and Pfdhfr mutations
The SNPs in the Pfdhfr and Pfdhps genes were detected 
by a combination of nested PCR and sequence specific 
oligonucleotide probe (SSOP)-ELISA analysis as previ-
ously described [34]. The SNPs analysed were Pfdhfr at 
codons C50R, N51I, C59R, S108N, and L164I, and Pfdhps 
at codons S436A, A437G, K540E, A581G and A613S.
Ethical issues
The studies which contributed specimens were approved 
by the Tanzanian Medical Research Coordinating Com-
mittee of (MRCC) hosted by the National Institute for 
Medical Research, Tanzania (NIMR). Permission to con-
duct the study in the three districts was obtained from 
the relevant regional and district authorities while the 
heads of the health facilities gave the permission to con-
duct the study at the respective sites. Prior to enrolment, 
written informed consent was obtained from each indi-
vidual or from parents/legally acceptable representative 
in case of children.
Data analysis
Microsoft Access version 2007 and Excel databases were 
utilized for data management with double entry, valida-
tion and cleaning of the field and laboratory data. Statisti-
cal analyses were done using STATA version 11 (STATA 
Corp Inc., TX, USA). Characteristics of the study popu-
lation for the different sites were tested by analysis of 
variance (ANOVA). The prevalence of the genotypes 
was calculated as the proportion of wild type, mixed or 
mutants in the total analysable samples. Mixed infections 
with wild-type and mutant alleles were treated as mutant 
while generating the haplotype prevalence. Prevalence of 
mutations and haplotypes between sites were compared 
using Chi-square or Fisher’s exact test as appropriate. 
Statistical analyses were performed at the 5  % signifi-
cance level and 95 % Confidence Interval (CI).
Results
A total of 264 samples from the three sites (Muheza, 
Muleba and Nachingwea) were included in the analysis 
with each site contributing 88 samples. The demographic 
and parasitological characteristics of the study popula-
tion between the study sites were comparable (Table 1). 
The study populations were similar with respect to age 
(χ2 =  3.71, p =  0.16), gender (χ2 =  1.92, p =  0.38) and 
the mean haemoglobin levels (g/dL) (F = 2.5, p = 0.08). 
However, the geometric mean parasite density was signif-
icantly lower at Muleba compared to Muheza and Nach-
ingwea (F =  10.9, p  <  0.001), (Table  1). Fever at health 
facility presentation (temperature ≥ 37.5 °C) was signifi-
cantly higher at Muheza (χ2 = 8.37, p = 0.02) compared 
to Muleba and Nachingwea. Only a few patients reported 
prior history of AL (n = 13) or SP (n = 2) usage 2 weeks 
prior to enrolment into the study.
Prevalence of SNPs associated with SP resistance 
in Plasmodium falciparum dhfr and dhps genes
Significantly higher prevalence of Pfdhfr mutations at 
codons C50/N51I was detected at Muheza (100  %) and 
Muleba (98.8  %) compared to Nachingwea (67.5  %), 
(p  <  0.001). At Muheza, the Pfdhfr mutation at codon 
C59R had reached almost saturation level (96.6 %) while 
other sites, Muleba (73.1  %) and Nachingwea (81.8  %), 
had significantly lower prevalence (p < 0.001). For codon 
S108N, the prevalence was significantly higher at Muheza 
(98.7 %) and Nachingwea (95.5 %) compared to Muleba 
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(83.3 %) (p = 0.003). The Pfdhfr mutation at codon I164L 
was not detected at any site.
For the Pfdhps, significantly high prevalence of parasite 
carrying mutant at codons S436A/A437G was detected 
(79.8 %) at Muheza as compared to Muleba (22.2 %) while 
Nachingwea had none (p  <  0.001). However, Naching-
wea had significantly higher prevalence (61.4 %) of dou-
ble mutants S436A/A437G (p  <  0.001). The prevalence 
of Pfdhps K540E at Muheza was significantly higher 
(95.4 %) compared to the other sites (p < 0.001). Another 
Pfdhps mutation also associated with high level resist-
ance at codon A581G was significantly higher at Muheza 
(p  <  0.001) reaching 48.9  % in comparison to Muleba 
(3.9 %) and Nachingwea at which the mutations was not 
detected. Low prevalence of Pfdhps A613S was detected 
at Muleba (2/77, 2.6 %) and Nachingwea (1/82, 1.2 %).
Prevalence of the major Plasmodium falciparum dhfr 
and dhps haplotypes
Similarly, the prevalence of double mutant haplotypes 
(CICNI, CNRNI and CIRSI) was low except for Muleba 
where a significantly higher prevalence (23.6 %) of dou-
ble haplotype CICNI was reported compared to the 
other sites (p = 0.008). Overall, the triple Pfdhfr mutants 
(CIRNI) were predominant at all sites and almost near 
saturation at Muheza (93.3  %) but with significantly 
lower prevalence of and at Muleba (75 %) and Naching-
wea (70.6 %), (p < 0.001).
The prevalence of wildtype Pfdhps haplotype (SAKAA) 
was significantly low at Muheza (1.3  %) compared to 
other sites (p = 0.003). Similarly, the three major single 
mutant haplotypes were also low (Table  2). The double 
Pfdhps haplotype SGEAA was higher at Muheza (27.2 %) 
and Muleba (20.8 %) compared to Nachingwea (p < 0.001) 
while AAKAS was low at both site (p = 0.76). About 56 % 
of all isolates were triple mutants with Muheza having 
the highest prevalence of SGEGA haplotype compared 
to AGEAA which was more predominant at Muleba and 
Nachingwea (p < 0.001), (Table 2). The Pfdhps quadruple 
haplotypes AGEGA were generally low and varied signif-
icantly between the sites, whereby eight isolates (10.4 %) 
were detected at Muheza, two at Muleba (5.6  %) and 
none was detected at Nachingwea (p = 0.003) (Table 2).
Upon combination of the Pfdhfr-Pfdhps haplotypes 
(Table  3), quadruple mutant haplotypes with single 
Pfdhps and triple Pfdhfr mutation (AAKAA-CIRNI) was 
lowly distributed (n = 16) across all sites while the quin-
tuple mutant haplotype, CIRNI-SGEAA was observed in 
only 31 isolates, at Muheza and Muleba. Sextuple CIRNI-
SGEGA haplotypes (n  =  32) were more predominant 
in Muheza whereas other sextuple haplotype combina-
tions, (CIRNI-AGEAA (n =  69)) were mainly observed 
in Nachingwea. Interestingly, the emergence of the new 
septuple mutant haplotypes with three Pfdhfr and four 
Pfdhps mutant combination (CIRNI-AGEGA) was 
observed for the first time albeit in few samples (n = 11) 
and these were mainly from Muheza (n = 8) and (n = 3) 
were from Muleba whereas none was noted at Naching-
wea. The occurrences of other Pfdhps-Pfdhfr haplotypes 
were generally low (Table 3).
Discussion
The rapid and widespread anti-malarial drug resistance 
has necessitated frequent revisions of malaria treatment 
guidelines in P. falciparum malaria endemic regions. 
The emergence of super resistant mutations, such as the 
sextuple Pfdhfr/Pfdhps haplotypes has not only compro-
mised malaria case management and treatment outcomes 
but also affected the effectiveness of the IPT strategies.
Few years after its adoption as the first-line treatment 
drug for uncomplicated malaria in Tanzania, several effi-
cacy studies detected unacceptably high levels of molecu-
lar markers of parasite resistance to SP [4, 35]. Despite its 
replacement by ACT, SP continued to be used in the IPT 
Table 1 Demographic and parasitological characteristics of the study population in Tanzania
Significant values are in boldface
IQR inter-quartile range, GMPD geometric mean parasite density, asexual parasites/µL of blood
a One way ANOVA was used to test the differences between the study sites
Parameters Study site P value
Muheza (n = 88) Muleba (n = 88) Nachingwea (n = 88)
Median age (years) (25–75 % IQR) 4.2 (2.1–6.3) 4.4 (2.2–13.0) 5.2 (2.9–12.6) 0.16
Sex, female n (%) 42 (47.7) 48 (54.5) 51 (58.0) 0.38
Mean haemoglobin (g/dL), (SD)a 10.4 (1.8) 9.9 (2.4) 9.7 (2.4) 0.08
GMPD (95 % CI)a 18,603 (13,280–26,060) 3700 (1899–7211) 12,968 (8066–20,848) <0.001
Fever at presentation (≥37.5 °C), n (%) 65 (73.9) 59 (67.1) 47 (53.4) 0.02
Antimalarial treatment history, n (%) NA 10 (11.4) 5 (6.2) 0.23
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strategies which is likely to provide sub-optimal effect 
and, therefore, monitoring the spread of resistance using 
molecular markers (Pfdhfr/Pfdhps) is still recommended 
[36–38]. In this study, the prevalence of A581G was 
almost 50 % in Muheza and this was significantly higher 
compared to Muleba (~4 %) and Nachingwea (0 %). This 
could confirm the earlier suggestions that this “super 
resistant” mutation may have originated in the north-
eastern part of Tanzania and spread to other areas albeit 
at low prevalence [37].
A remarkable difference was observed in the preva-
lence of Pfdhps SNPs between the study sites with 
Muheza having the highest levels of Pfdhps 436/437SG, 
A581G, A540E SNPs and haplotypes compared to 
Table 2 P. falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) haplotypes by study sites
Bold underline indicates the amino acid changes
n number of haplotypes excluding the mixed infections/genotypes
* Pearson Chi-square test was applied (χ2 = 39.9, p < 0.001), all others were compared using Fisher’s exact test
Gene haplotype Prevalence of haplotypes by sites
Muheza (n = 77) Muleba (n = 72) Nachingwea (n = 85) P value
Pfdhfr CNCSI 0 (0) 0 (0) 3 (3.5) 0.109
CICNI 4 (5.2) 17 (23.6) 7 (8.4) 0.002
CIRSI 1 (1.3) 0 (0) 0 (0) 0.642
CNRNI 0 (0) 1 (1.4) 15 (17.7) <0.001
CIRNI 72 (93.3) 54 (75.0) 60 (70.6) <0.001
n = 77 n = 72 n = 82
Pfdhps SAKAA 1 (1.3) 11 (15.3) 11 (16.5) 0.003
AAKAA 4 (5.2) 4 (5.6) 16 (18.8) 0.008
SAKAS 0 (0) 1 (1.4) 0 (0) 0.308
SAEAA 0 (0) 4 (5.6) 0 (0) 0.008
AAKAS 0 (0) 1 (1.4) 1 (1.2) 0.76
SGEAA 21 (27.2) 15 (20.8) 0 (0) <0.001
SGEGA 31 (40.3) 2 (2.8) 0 (0) <0.001
AGEAA 12 (15.6) 30 (41.7) 54 (63.5) <0.001*
AGEGA 8 (10.4) 4 (5.6) 0 (0) 0.003
Table 3 The pattern of combined P. falciparum dhfr–dhps haplotypes
The overall numbers (absolute) parasite haplotypes on the Pfdhfr–Pfdhps genes in the samples successfully analysed (n = 234). Of all the combined haplotypes, the 
quintuple CIRNI-SGEAA, sextuple CIRNI-AGEAA, CIRNI-SGEGA were more frequently detected
Bold underline indicates the amino acid changes, while SAKAA and CNCSI represent the wildtype haplotype for Pfdhps and Pfdhfr, respectively
Pfdhps haplotypes Pfdhfr haplotypes Total
Wild-type Double Triple
CNCSI CICNI CIRSI CNRNI CIRNI
Wildtype SAKAA 0 4 0 2 20 26
Single AAKAA 1 3 0 4 16 24
SAEAA 0 0 0 0 4 4
SAKAS 0 0 0 0 1 1
Double SGEAA 0 5 0 0 31 36
AAKAS 0 0 0 0 2 2
Triple SGEGA 0 1 0 0 32 33
AGEAA 2 14 1 10 69 96
Quadruple AGEGA 0 1 0 0 11 12
Total 3 28 1 16 186 234
Page 7 of 9Baraka et al. Malar J  (2015) 14:439 
Muleba and Nachingwea. As expected areas with high 
malaria transmission intensities in Muleba and Naching-
wea had higher prevalence of Pfdhps wild types and sin-
gle mutant 436/437AG as compared to Muheza in north 
eastern where malaria endemicity has declined remark-
ably in recent years [39, 40]. The current WHO recom-
mendations suggest that SP-IPTp should be discontinued 
if the prevalence of this double Pfdhps mutant, K540E is 
more than 95 % and the A581G is more than 10 % as it is 
considered to be ineffective [29]. Obviously, these criteria 
are still met in Muheza confirming the findings of previ-
ous studies conducted in north Eastern Tanzania [26]. In 
a cohort study conducted at Muheza, it was shown that 
IPTp–SP was associated with increased prevalence of 
parasites with mutations at codon A581G and that use 
of IPTp-SP conferred no benefit in improvement of preg-
nancy outcomes [17, 37]. Of note, this area is known to 
be the major focus of Pfdhps A581G mutations in East 
Africa which is believed to occur almost exclusively with 
Pfdhfr K540E leading to double mutant haplotypes [41]. 
The high frequency of Pfdhps A581G at alarming level 
in this area clearly suggests for no beneficial protective 
effect from the IPTp-SP [17, 18, 42]. This higher preva-
lence in north eastern Tanzania could be explained by the 
sustained drug pressure due to self-medication that could 
have elevated levels of SP resistance, Ringsted et al. [43] 
reported 76 % volume sales of SP in private drug shops 
in this areas. Additionally, the high prevalence levels 
could be maintained due to selective pressure on Pfdhfr 
and Pfdhps as a result of co-trimoxazole (trimethoprim-
sulfamethoxazole), another antifolate, used to prevent 
opportunistic infections in HIV infected individuals as 
cross-resistance might also occur [44, 45].
The prevalence of the Pfdhfr-Pfdhps wild type hap-
lotypes was low in all sites. The prevalence of mutant 
genotypes C51I, was at saturation in Muheza (100  %) 
and equally at Muleba (98.8  %) with significantly lower 
prevalence (67.5  %) at Nachingwea (p  <  0.001). Simi-
larly, almost complete saturation (>96 %) of other muta-
tions in Pfdhfr (N51I, C59R, and S108 N) was observed 
at Muheza with marked differences between Muleba and 
Nachingwea (Table  2). In contrast, some previous stud-
ies have shown that other major resistance mutations in 
Pfdhfr are well established throughout the country where 
the Pfdhfr triple mutations (51I, 59R and 108N) were 
above 84 % and close to saturation in six regions of Tan-
zania [46]. Elsewhere, these data are in consistent with 
studies in West Africa where Pfdhfr N51I, N59R, and 
S108N have been shown to rise [19]. The prevalence of 
I164L mutation conferring high pyrimethamine resist-
ance was not detected at all the three sites which is in 
accordance to previous reports elsewhere [47]. However, 
in other parts of Africa, only a few studies have reported 
occurrence of this high level mutation [15, 16, 48]. Of 
note, the Pfdhfr I164L mutation was first documented at 
low prevalence in Muheza in 1999 before the deployment 
of IPTp-SP [49] and later one isolate (mixed allele) was 
reported in Rufiji [50], but to date its presence has rarely 
been reported in the country.
The CIRNI haplotype with triple mutations was present 
and highly prevalent at all study sites regardless of the 
transmission intensity. This is in line with several stud-
ies in Tanzania and elsewhere in the SSA [51, 52]. The 
CIRNI haplotype is associated with high level resistance 
to pyrimethamine and increases the risk of SP resistance 
if it occurs concurrently with Pfdhps mutations [21]. The 
increased double mutant Pfdhps SGEAA haplotype was 
observed in Muheza (28 %) and Muleba (22 %), but not in 
Nachingwea (0 %). In Muheza, the highly resistant triple 
SGEGA Pfdhps haplotypes was observed, (38.7 %).
The combinations of Pfdhfr-Pfdhps were detected at 
higher numbers including quintuple mutant CIRNI-
SGEAA, sextuple haplotype which comprise triple muta-
tions in both genes CIRNI-SGEGA and CIRNI-AGEGA 
have been highly associated with sub-optimal IPTp-SP 
effectiveness in previous studies [17]. Interestingly, a sep-
tuple mutant haplotype CIRNI-AGEGA was observed 
which had not been previously reported in the study 
areas. From these observations, it is apparent that these 
mutant haplotypes associated with poor IPTp-SP are 
expanding in different epidemiological settings. Of worth 
noting, this study was not designed to correlate the clini-
cal data with observed resistance pattern. Nonetheless 
previous literature showing the association of these hap-
lotypes with clinical or treatment outcomes have been 
noted.
Ideally, in order to reduce the sustained drug pres-
sure, efforts are required to limit the use of SP for IPTp 
purposes only through limiting over the counter SP pre-
scriptions. Also the availability of ACT for the treatment 
of uncomplicated malaria and proper implementation of 
the national malaria treatment guidelines would also con-
tribute in the reducing the selection pressure. However, 
alternative drugs for IPTp are urgently needed to replace 
the failing SP due to the saturation of the parasite popula-
tion with Pfdhps-Pfdhfr mutations and haplotypes highly 
associated with SP resistance. Deployment of the sub-
optimal IPTp-SP strategy is therefore unlikely to confer 
the anticipated effect on improving pregnancy outcomes.
Conclusion
These results ascertain the high prevalence of Pfdhfr and 
Pfdhps haplotypes conferring SP resistance in areas with 
changing malaria epidemiology. The high prevalence of 
Pfdhfr-Pfdhps sextuple mutant haplotypes and the occur-
rence of the new septuple mutant haplotype undermine 
Page 8 of 9Baraka et al. Malar J  (2015) 14:439 
the usefulness of IPTp-SP. Thus, additional control efforts 
are needed to contain the spread of SP resistance and 
suitable alternative drugs for IPTp are urgently needed.
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